for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Corcept Therapeutics Incorporated

CORT.OQ

Latest Trade

16.11USD

Change

0.18(+1.13%)

Volume

343,105

Today's Range

15.85

 - 

16.31

52 Week Range

9.14

 - 

19.48

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Corcept Therapeutics Posts Q3 Adj Earnings Per Share Of $0.31

Nov 7 (Reuters) - Corcept Therapeutics Inc <CORT.O>::CORCEPT THERAPEUTICS ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 NON-GAAP EARNINGS PER SHARE $0.31.Q3 GAAP EARNINGS PER SHARE $0.22.Q3 REVENUE $81.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $78 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $0.20 -- REFINITIV IBES DATA.SEES Q3 REVENUE $81.5 MILLION.SEES FY 2019 REVENUE $300 MILLION TO $315 MILLION.FY2019 REVENUE VIEW $298.5 MILLION -- REFINITIV IBES DATA.

Corcept Therapeutics Q3 Non-GAAP Earnings Per Share $0.31

Nov 7 (Reuters) - Corcept Therapeutics Inc <CORT.O>::CORCEPT THERAPEUTICS ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 NON-GAAP EARNINGS PER SHARE $0.31.Q3 GAAP EARNINGS PER SHARE $0.22.Q3 REVENUE $81.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $78 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $0.20 -- REFINITIV IBES DATA.REPORTS Q3 REVENUE $81.5 MILLION.SEES FY 2019 REVENUE $300 MILLION TO $315 MILLION.FY2019 REVENUE VIEW $298.5 MILLION -- REFINITIV IBES DATA.

Corcept Therapeutics Reports Q2 Non-GAAP Earnings Per Share Of $0.25

Aug 1 (Reuters) - Corcept Therapeutics Inc <CORT.O>::CORCEPT THERAPEUTICS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 NON-GAAP EARNINGS PER SHARE $0.25.Q2 GAAP EARNINGS PER SHARE $0.17.SEES FY 2019 REVENUE $285 MILLION TO $315 MILLION.Q2 REVENUE $72.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $70.9 MILLION.SEES Q3 2019 REVENUE $72.3 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $0.18 -- REFINITIV IBES DATA.

Corcept Therapeutics Reports Q2 GAAP Earnings Per Share of $0.17

Aug 1 (Reuters) - Corcept Therapeutics Inc <CORT.O>::CORCEPT THERAPEUTICS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 NON-GAAP EARNINGS PER SHARE $0.25.Q2 GAAP EARNINGS PER SHARE $0.17.CORCEPT THERAPEUTICS - REPORTS Q2 REVENUE OF $72.3 MILLION .SEES FY 2019 REVENUE $285 MILLION TO $315 MILLION.Q2 REVENUE $72.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $70.9 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $0.18 -- REFINITIV IBES DATA.

Corcept Therapeutics says Received Paragraph IV Notice Letter Advising Sun Pharmaceutical Industries Submitted ANDA To U.S. FDA

June 11 (Reuters) - Corcept Therapeutics Inc <CORT.O>::CORCEPT THERAPEUTICS - RECEIVED PARAGRAPH IV NOTICE LETTER ADVISING SUN PHARMACEUTICAL INDUSTRIES SUBMITTED ANDA TO U.S. FDA.CORCEPT - NOTICE LETTER ALLEGES THAT KORLYM PATENTS WILL NOT BE INFRINGED BY SUN PHARMA'S PROPOSED PRODUCT, ARE INVALID AND/OR ARE UNENFORCEABLE.CORCEPT THERAPEUTICS - ABBREVIATED NEW DRUG APPLICATION SEEKS AUTHORIZATION FROM FDA TO MANUFACTURE, USE OR SELL GENERIC VERSION OF KORLYM IN U.S..

Corcept Therapeutics Q1 Non-GAAP Earnings Per Share $0.20

May 9 (Reuters) - Corcept Therapeutics Inc <CORT.O>::CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 NON-GAAP EARNINGS PER SHARE $0.20.Q1 GAAP EARNINGS PER SHARE $0.15.SEES FY 2019 REVENUE $285 MILLION TO $315 MILLION.Q1 REVENUE $64.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $69.3 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $0.19 -- REFINITIV IBES DATA.SEES Q2 2019 REVENUE $64.8 MILLION.FY2019 REVENUE VIEW $302.6 MILLION -- REFINITIV IBES DATA.Q2 REVENUE VIEW $73.2 MILLION -- REFINITIV IBES DATA.

Corcept Therapeutics Sees FY 2019 Revenue Of $285 Mln TO $315 Mln

Feb 25 (Reuters) - Corcept Therapeutics Inc <CORT.O>::CORCEPT THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2018 AUDITED FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 GAAP EARNINGS PER SHARE $0.18.SEES FY 2019 REVENUE $285 MILLION TO $315 MILLION.Q4 REVENUE $66.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $69.6 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $0.15 -- REFINITIV IBES DATA.REITERATED 2019 REVENUE GUIDANCE OF $285 - 315 MILLION.

Corcept Therapeutics Reports Q4 Revenue $66.8 Mln

Jan 31 (Reuters) - Corcept Therapeutics Inc <CORT.O>::CORCEPT THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2018 PRELIMINARY SELECTED FINANCIAL RESULTS; PROVIDES 2019 REVENUE GUIDANCE.Q4 REVENUE $66.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $70.4 MILLION.SEES FY 2019 REVENUE $285 MILLION TO $315 MILLION.2019 REVENUE GUIDANCE OF $285 - $315 MILLION.

Corcept Therapeutics Reports Q3 GAAP Earnings Per Share Of $0.14

Nov 1 (Reuters) - Corcept Therapeutics Inc <CORT.O>::CORCEPT THERAPEUTICS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 NON-GAAP EARNINGS PER SHARE $0.22.Q3 GAAP EARNINGS PER SHARE $0.14.Q3 REVENUE $64.4 MILLION VERSUS I/B/E/S VIEW $67.4 MILLION.REPORTS Q3 REVENUE $64.4 MILLION.Q3 EARNINGS PER SHARE VIEW $0.17 -- THOMSON REUTERS I/B/E/S.REAFFIRMED 2018 REVENUE GUIDANCE OF $250-270 MILLION.FY2018 REVENUE VIEW $260.8 MILLION -- THOMSON REUTERS I/B/E/S.

Judge Denies Teva Pharmaceuticals’ Motion To Dismiss Corcept Therapeutics’ Allegations Of Patent Infringement

Oct 24 (Reuters) - Corcept Therapeutics Inc <CORT.O>::JUDGE DENIES TEVA PHARMACEUTICALS’ MOTION TO DISMISS CORCEPT THERAPEUTICS’ ALLEGATIONS OF PATENT INFRINGEMENT.CORCEPT THERAPEUTICS INC - JUDGE WIGENTON'S DENIAL OF TEVA'S MOTION MEANS THAT CORCEPT'S LAWSUIT WILL PROCEED.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up